Enhanced 9-(2-phosphonylmethoxyethyl)adenine secretion by a specific, indomethacin-sensitive efflux pump in a mutant 9-(2- phosphonylmethoxyethyl)adenine-resistant human erythroleukemia K562 cell line

Molecular Pharmacology

Volumn 54, Issue 5, 1998, Pages 907-917

  Hatse, Sigrid ^a   De Clercq, Erik ^a   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; DACTINOMYCIN; GLYCOPROTEIN P; INDOMETACIN; MULTIDRUG RESISTANCE PROTEIN; ZIDOVUDINE;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG PENETRATION; DRUG SPECIFICITY; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; ISOTOPE LABELING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA SYNTHESIS; TEMPERATURE DEPENDENCE;

EID: 0031725103     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.5.907     Document Type: Article

References (28)

1. Annaert P, van Gelder J, Naesens L, De Clercq E, Van den Mooter G, Kinget R, and Augustijns P (1998) Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. Pharm Res 15:1168-1173.
2. Balzarini J, Hao Z, Herdewijn P, Johns DG, and De Clercq E (1991) Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonyl-methoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci USA 88:1499-1503.
3. Balzarini J, Hatse S, Naesens L, and De Clercq E (1998) Selection and characterization of murine leukemia L1210 cells with high-level resistance to the cytostatic activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)-adenine (PMEA). Biochim Biophys Acta 1402:29-38.
4. Balzarini J, Verstuyf A, Hatse S, Goebels J, Sobis H, Vandeputte M, and De Clercq E (1995) The human immunodeficiency virus (HIV) inhibitor 9-(2-phosphonylmethoxyethyl)adenine (PMEA) is a strong inducer of differentiation of several tumor cell lines. Int J Cancer 61:130-137.
5. Barditch-Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS, and Lietman PS (1997) Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of Adefovir Dipivoxil (9-[2-(bis-pivaloyloxymethyl)phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Inf Dis 176:406-413.
6. Bhalla K, Nayak R, and Grant S (1984) Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-D-arabinofuranosylcytosine. Cancer Res 44:5029-5037.
7. Berger SH, Jenh CH, Johnson LF, and Berger FG (1985) Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 28:461-467.
8. Casara P, Altenburger J-M, Taylor DL, Tyms AS, Kenny M, and Navé J-F (1995) Synthesis and antiviral activity of rigid acyclonucleotide analogs. Bioorg Med Chem Lett 5:1275-1280.
9. Collington GK, Hunter J, Allen CN, Simmons NL, and Hirst BH (1992) Polarized efflux of 2',7'-bis(2-carboxyethyl)-5(6)-carboxyfluorescein from cultured epithelial cell monolayers. Biochem Pharmacol 44:417-424.
10. De Clercq E, Holý A, Rosenberg I, Sakuma T, Balzarini J, and Maudgal PC (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature (Lond) 323:464-467.
11. Fardel O, Escande F, Drenou B, Le Bescot J, Rault B, and Fauchet R (1995) Expression of P-glycoprotein in multidrug-resistant human leukemia K562 cells during erythroid differentiation. Int J Oncology 7:377-381.
12. Gottesman MM, and Pastan I (1988) The multidrug transporter, a double-edged sword. J Biol Chem 262:12163-12166.
13. Hatse S, Balzarini J, and De Clercq E (1995) Induction of erythroid differentiation of human leukemia K562 cells by the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine (PMEA). Nucleosides Nucleotides 14:649-652.
14. Hatse S, De Clercq E, and Balzarini J (1996) Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells. Mol Pharmacol 50:1231-1242.
15. Hatse S, Naesens L, De Clercq E, and Balzarini J (1998a) Potent differentiation-inducing properties of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in the rat choriocarcinoma RCHO tumor cell model. Biochem Pharmacol, in press.
16. Hatse S, Naesens L, Degrève B, Segers C, Vandeputte M, Waer M, De Clercq E, and Balzarini J (1998b) Potent antitumor activity of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl) in choriocarcinoma-bearing rats. Int J Cancer 76:595-600.
17. Ho HT, De Boeck H, Woods KL, Konrad SA, Brankovan V, and Hitchcock MJM (1991) Structure and activity correlation-studies of anti-HIV acyclic guanine nucleotide analogs at enzyme level. Antivir Res 15(Suppl 1):95.
18. Holý A and Rosenberg I (1987) Synthesis of 9-(2-phosphonylmethoxyethyl)adenine and related compounds. Collect Czech Chem Commun 52:2801-2809.
19. Lautier D, Canitrot Y, Deeley RG, and Cole SPC (1996) Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52:967-977.
20. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, and De Clercq E (1997) HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir Chem Chemother 8:1-23.
21. Navé J-F, Casara PJ, Taylor DL, Tyms AS, Kenny M, and Halazy S (1996) Synthesis, enzymatic phosphorylation and antiviral activity of acyclic dienyl phosphonate derivatives of guanine. Bioorg Med Chem Lett 6:179-184.
22. Palú G, Stefanelli S, Rassu M, Parolin C, Balzarini J, and De Clercq E (1991) Cellular uptake of phosphonylmethoxyalkylpurine derivatives. Antivir Res 16:115-119.
23. Pisarev VM, Lee SH, Connelly MC, and Fridland A (1997) Intracellular metabolism and action of acyclic nucleoside phosphonates on DNA replication. Mol Pharmacol 52:63-68.
24. Robbins BL, Connelly MC, Marshall DR, Srinivas RV, and Fridland A (1995a) A human T lymphoid cell variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. Mol Pharmacol 47:391-397.
25. Robbins BL, Greenhaw J, Connelly M, and Fridland A (1995b) Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob Agents Chemother 39:2304-2308.
26. Srinivas RV, Robbins BL, Connelly MC, Gong Y-F, Bischofberger N, and Fridland A (1993) Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob Agents Chemother 37: 2247-2250.
27. Twentyman PR, and Versantvoor CHM (1996) Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance. Eur J Cancer 32A: 1002-1009.
28. Zaman GJR, Flens MJ, Van Leusden MR, De Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ, and Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91:8822-8826.